Merck KGaA stock falls after cancer trial setback
2024-06-25
Anne Czichos Shares of Merck KGaA (OTCPK:MKGAF) (OTCPK:MKKGY) fell in European trading on Tuesday after the German drugmaker said it would discontinue a late-stage trial for its head and neck cancer therapy xevinapant as its early results indicated a potential failure. The decision comes after the study’s data monitoring committeeContinue Reading